Vinge advises EQT in connection with the acquisition of leading global pest control specialist Anticimex which becomes the first investment of EQT’s new purpose-driven strategy with longer-term investments and impact at its core.

Anticimex is a modern service company working with pest control, food safety, damp control, house inspections and fire protection. Anticimex has since 1934 developed from being a Swedish family business to an international company with over 4,500 employees in 17 countries. The transaction, where the selling party is the EQT VI fund, has an enterprise value of SEK 60 billion and the investment is made together with several long-term investors, such as Melker Schörling AB (MSAB), who will be the second largest shareholder, GIC, AMF, Interogo Holding Long-Term Equity and Alecta.

Vinge’s team consists of Christina Kokko and Peter Sundgren together with Maria Dahlin Kolvik, Ellinor Wargenbrant, Manne Bergström and Nando Basic (M&A/Corporate), Louise Brorsson Salomon, Seyran Sahin, Karl-Gustaw Tobola and Axel Jansson (Banking and Finance), Viveka Classon, Paulina Malmberg and David Lundahl (Corporate Insurance), Emma Stuart-Beck, Caroline Krassén and Elias Bohlin (Financial Services), Sofia Bergenstråhle (IPR), Isabell Nielsen (Commercial Agreements), Elin Broman (Employment), Lina Österberg and Ulf Pyk (Real Estate and Environment), Mika Jordan (IT), Nicklas Thorgerzon (GDPR) and Jessica Öijer (VDR). Partner Marcus Glader together with Emma Johansson and Johan Wahlbom advice in relation to merger filing.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025